David A. Sinclair
PulseAugur coverage of David A. Sinclair — every cluster mentioning David A. Sinclair across labs, papers, and developer communities, ranked by signal.
- 2026-06-09 research_milestone David Sinclair plans to initiate human trials for a whole-body rejuvenation drug as part of the XPrize Healthspan Competition. source
- 2026-06-09 research_milestone David Sinclair plans to initiate human trials for an oral rejuvenation drug as part of the XPrize Healthspan Competition. source
-
Longevity research attracts billions for cellular rejuvenation therapies
Scientists are exploring methods to reverse aging by returning cells to a younger state, attracting significant investment. This field, known as longevity research, is rapidly advancing with experimental treatments aimi…
-
Longevity field's cellular reprogramming theory faces human trial reality check
A groundbreaking human trial has begun for a gene therapy aimed at partially reprogramming older cells to a younger state, a development that could validate key theories in the longevity medicine field. This early-stage…
-
MIT Tech Review: Cell reprogramming for aging reversal and interoception research gain momentum
MIT Technology Review's newsletter, The Download, highlights two emerging areas of scientific research: the "reprogramming" of cells to reverse aging and the study of interoception, the internal sense of bodily feelings…
-
OpenAI Files for $1 Trillion IPO Amid AI and Longevity News
MIT Technology Review's daily newsletter, The Download, covers significant developments in AI and longevity research. The publication highlights OpenAI's confidential filing for a US IPO, potentially valuing the company…
-
David Sinclair to test oral rejuvenation drug in XPrize competition
Longevity scientist David Sinclair is preparing to test an oral drug mixture, code-named SL-100, for whole-body rejuvenation. This initiative is part of a $101 million XPrize competition aimed at restoring individuals t…